BALTIMORE, MD--(Marketwired - Sep 25, 2013) - In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that for investors seeking a well-positioned mid-late stage biotechnology company, one may not need to go any further than Nuvilex, Inc. (
Savvy biotech investors typically engage a checklist of sorts in order to ascertain a given biotech's standing and worthiness (and occasionally valuation). These attributes include intellectual property ownership, clinical trial development and completion, trial performance results as compared with competing firms, size of targeted treatment market, mechanism of action of drug or biologics, applicability of approach for other treatment categories, management, third party/strategic partner funding history, and upcoming milestones.
Based on the list above it is clear that Nuvilex stands perched near the top of the mid-late stage biotech standings.
For example, the Company owns exclusive rights to a ground-breaking targeted drug delivery system that may be used to develop treatments for many different types of cancer. Results for highly successful Phase II clinical trials using this technology to treat inoperable pancreatic cancer included superior median survival time and one-year survival rate than those reported for the 3 approved pancreatic cancer treatments. Moreover, the striking results in the Nuvilex trials were achieved using low chemotherapy doses, which markedly reduced the side effects from the cancer drug.
The pancreatic cancer treatment market alone is in excess of $1B and given the potential to use the therapy to treat other cancers, Nuvilex is a pure-play cancer treatment stock. Plus, there are indications that the live-cell encapsulation technology can be used to treat diabetes. To that end, the Company is nearing closure of a deal to secure the technology for diabetes as well, substantially increasing the size of the market opportunity for the Company. Therefore, Nuvilex is no one-trick pony.
At the current stage, investors can place a check mark next to all of the boxes with the exception of a strategic partner. However, strategic partnerships usually are accompanied by the commencement or conclusion of major developmental events. As a result, a third-party investment/partnership with the likes of oncology-focused firms such as Celgene, Merck, Bristol-Myers Squibb, and others is clearly in the cards, which makes Nuvilex's shares that much more attractive, ahead of such an event that typically drives stocks and valuations substantially higher.
This press release contains excerpts of our most recently published article on Nuvilex. To view all of our sponsored Nuvilex reports, updates, articles, disclosures and disclaimers, or to download the article in its entirety, please visit www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (